{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T05:22:26Z","timestamp":1732944146040,"version":"3.30.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,29]]},"DOI":"10.7759\/cureus.74782","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T01:18:09Z","timestamp":1732929489000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Drug-Induced Lupus in Crohn\u2019s Disease During Infliximab Therapy"],"prefix":"10.7759","author":[{"given":"Tomotaka","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syohei","family":"Ishimaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Arataki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.07.005","article-title":"Drug-induced lupus: an update","volume":"10","author":"Katz U","year":"2010","unstructured":"Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev. 2010, 10:46-50. 10.1016\/j.autrev.2010.07.005","journal-title":"Autoimmun Rev"},{"key":"ref2","article-title":"Drug induced lupus","volume":"41","author":"Miyagawa F","year":"2021","unstructured":"Miyagawa F. Drug induced lupus. Allergy in Practice. 2021, 41:1274-77.","journal-title":"Allergy in Practice"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.11.012","article-title":"Drugs and autoimmunity--a contemporary review and mechanistic approach","volume":"34","author":"Chang C","year":"2010","unstructured":"Chang C, Gershwin ME. Drugs and autoimmunity--a contemporary review and mechanistic approach. J Autoimmun. 2010, 34:J266-75. 10.1016\/j.jaut.2009.11.012","journal-title":"J Autoimmun"},{"key":"ref4","article-title":"Drug induced lupus caused by TNF-\u03b1 inhibitors","volume":"42","author":"Miyagawa F","year":"2022","unstructured":"Miyagawa F. Drug induced lupus caused by TNF-\u03b1 inhibitors. Allergy in Practice. 2022, 42:368-70.","journal-title":"Allergy in Practice"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-008-0895-5","article-title":"Drug-induced lupus erythematosus","volume":"301","author":"Vedove CD","year":"2009","unstructured":"Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009, 301:99-105. 10.1007\/s00403-008-0895-5","journal-title":"Arch Dermatol Res"},{"key":"ref6","unstructured":"Drug and erythematosus. (2015). https.\/\/www.zenniti.com\/."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg MC","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40:1725. 10.1002\/art.1780400928","journal-title":"Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1422.019","article-title":"Drug-induced lupus","volume":"1108","author":"Borchers AT","year":"2007","unstructured":"Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci. 2007, 1108:166-82. 10.1196\/annals.1422.019","journal-title":"Ann N Y Acad Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502445","article-title":"Essential requirement for IFN regulatory factor 7 in autoantibody production but not development of nephritis in murine lupus","volume":"197","author":"Miyagawa F","year":"2016","unstructured":"Miyagawa F, Tagaya Y, Ozato K, Asada H. Essential requirement for IFN regulatory factor 7 in autoantibody production but not development of nephritis in murine lupus. J Immunol. 2016, 197:2167-76. 10.4049\/jimmunol.1502445","journal-title":"J Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka AK","year":"2005","unstructured":"Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A. 2005, 102:3372-7. 10.1073\/pnas.0408506102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.08.003","article-title":"Drug-induced lupus due to anti-tumor necrosis factor alpha agents","volume":"37","author":"Costa MF","year":"2008","unstructured":"Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum. 2008, 37:381-7. 10.1016\/j.semarthrit.2007.08.003","journal-title":"Semin Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328010c547","article-title":"Syndromes and complications of interferon therapy","volume":"19","author":"Borg FA","year":"2007","unstructured":"Borg FA, Isenberg DA. Syndromes and complications of interferon therapy. Curr Opin Rheumatol. 2007, 19:61-6. 10.1097\/BOR.0b013e328010c547","journal-title":"Curr Opin Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-004-0542-1","article-title":"Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity","volume":"26","author":"Caramaschi P","year":"2006","unstructured":"Caramaschi P, Biasi D, Colombatti M, et al.. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int. 2006, 26:209-14. 10.1007\/s00296-004-0542-1","journal-title":"Rheumatol Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals M","year":"2007","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Mu\u00f1oz S, et al.. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007, 86:242-51. 10.1097\/MD.0b013e3181441a68","journal-title":"Medicine (Baltimore)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune diseases induced by TNF-targeted therapies","volume":"22","author":"Ramos-Casals M","year":"2008","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008, 22:847-61. 10.1016\/j.berh.2008.09.008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1361.100","article-title":"Autoimmunity and anti-TNF-alpha agents","volume":"1051","author":"Atzeni F","year":"2005","unstructured":"Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci. 2005, 1051:559-69. 10.1196\/annals.1361.100","journal-title":"Ann N Y Acad Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21362","article-title":"Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-\u03b1 antibody-treated patients with inflammatory bowel disease","volume":"17","author":"Beigel F","year":"2011","unstructured":"Beigel F, Schnitzler F, Paul Laubender R, et al.. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-\u03b1 antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011, 17:91-8. 10.1002\/ibd.21362","journal-title":"Inflamm Bowel Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1365-y","article-title":"Tumour necrosis factor inhibitor-related lupus: safety of switching agents","volume":"29","author":"Luong JM","year":"2010","unstructured":"Luong JM, Tan BT, Buchanan RR, Schachna L. Tumour necrosis factor inhibitor-related lupus: safety of switching agents. Clin Rheumatol. 2010, 29:551-3. 10.1007\/s10067-009-1365-y","journal-title":"Clin Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21370","article-title":"Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent","volume":"17","author":"Subramanian S","year":"2011","unstructured":"Subramanian S, Yajnik V, Sands BE, Cullen G, Korzenik JR. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis. 2011, 17:99-104. 10.1002\/ibd.21370","journal-title":"Inflamm Bowel Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/321681-a-case-of-drug-induced-lupus-in-crohns-disease-during-infliximab-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T01:18:11Z","timestamp":1732929491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/321681-a-case-of-drug-induced-lupus-in-crohns-disease-during-infliximab-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.74782","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}